170 related articles for article (PubMed ID: 31333127)
21. Improving statins production: From non-genetic strategies to genetic strategies.
Fan D; Tang H; Yang X; Zhao F; Han S
Biotechnol J; 2023 Dec; 18(12):e2300229. PubMed ID: 37563745
[TBL] [Abstract][Full Text] [Related]
22. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
23. Biosynthesis of Novel Statins by Combining Heterologous Genes from Xylaria and Aspergillus.
Itoh H; Matsui M; Miyamura Y; Takeda I; Ishii J; Kumagai T; Machida M; Shibata T; Arita M
ACS Synth Biol; 2018 Dec; 7(12):2783-2789. PubMed ID: 30403849
[TBL] [Abstract][Full Text] [Related]
24. Genome editing approaches: manipulating of lovastatin and taxol synthesis of filamentous fungi by CRISPR/Cas9 system.
El-Sayed ASA; Abdel-Ghany SE; Ali GS
Appl Microbiol Biotechnol; 2017 May; 101(10):3953-3976. PubMed ID: 28389711
[TBL] [Abstract][Full Text] [Related]
25. Lovastatin biosynthesis by Aspergillus terreus in a chemically defined medium.
Hajjaj H; Niederberger P; Duboc P
Appl Environ Microbiol; 2001 Jun; 67(6):2596-602. PubMed ID: 11375168
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the outcomes of submerged co-cultivation: production of lovastatin and other secondary metabolites by Aspergillus terreus in fungal co-cultures.
Boruta T; Milczarek I; Bizukojc M
Appl Microbiol Biotechnol; 2019 Jul; 103(14):5593-5605. PubMed ID: 31098686
[TBL] [Abstract][Full Text] [Related]
27. [Statins have other beneficial properties besides their cholesterol lowering effect].
Eriksson M
Lakartidningen; 1998 Aug; 95(35):3670-2. PubMed ID: 9748780
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Turner NA; Midgley L; O'Regan DJ; Porter KE
J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
[TBL] [Abstract][Full Text] [Related]
29. On the factors modulating the effect of statins on malignant cell proliferation.
Bessler H; Salman H; Bergman M; Djaldetti M
Cancer Invest; 2007 Aug; 25(5):279-84. PubMed ID: 17661201
[TBL] [Abstract][Full Text] [Related]
30. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
31. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
32. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
Bottorff MB; Yenkowsky JP; Cave DG
Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
[TBL] [Abstract][Full Text] [Related]
33. [Statins: similarities and differences in the pharmacological, clinical and laboratory aspects].
Motti C; Gnasso A; Cortese C
Ann Ital Med Int; 2000; 15(1):96-102. PubMed ID: 10842898
[TBL] [Abstract][Full Text] [Related]
34. Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
Crespo MJ; Quidgley JA
Pharmacology; 2006; 76(3):141-7. PubMed ID: 16428899
[TBL] [Abstract][Full Text] [Related]
35. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR
Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307
[TBL] [Abstract][Full Text] [Related]
36. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?
Christians U; Jacobsen W; Floren LC
Pharmacol Ther; 1998 Oct; 80(1):1-34. PubMed ID: 9804052
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
38. Effects of fungal statins on high-glucose-induced mouse mesangial cell hypocontractility may involve filamentous actin, t-complex polypeptide 1 subunit beta, and glucose regulated protein 78.
Hwang JC; Chang LC; Lin YF; Shui HA; Chen JS
Transl Res; 2010 Aug; 156(2):80-90. PubMed ID: 20627192
[TBL] [Abstract][Full Text] [Related]
39. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
40. Simvastatin and lovastatin, but not pravastatin, interact with MDR1.
Sakaeda T; Takara K; Kakumoto M; Ohmoto N; Nakamura T; Iwaki K; Tanigawara Y; Okumura K
J Pharm Pharmacol; 2002 Mar; 54(3):419-23. PubMed ID: 11902809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
